WASHINGTON — Prophylaxis with oral vancomycin (Vancocin) appeared to protect at-risk patients from experiencing a recurrence of Clostridium difficile infection, researchers reported here.

In a retrospective review of cases, one of 71 patients (1%) given prophylaxis with oral vancomycin, paired with antibiotic therapy, experienced recurrence of C. difficile compared with 35 (37%) out of 132 patients not given the prophylaxis (P<0.001), said Nicholas Van Hise, PharmD, from the University of Indiana Medical School in Indianapolis, and colleagues.

“It doesn’t taste real great, but patients tolerate it, because they would rather have the drug than another bout of C. difficile,” co-author Alex Bryant, PharmD, from Mercy Hospital St. Louis, told MedPage Today.

Continue Reading

READ FULL ARTICLE Curated publisher From Medical Page Today